The commercial traction of Emrosi™ is validating the company's dermatology-focused strategy. Traders should monitor prescription growth and payer coverage expansion in Q1 2026 as leading indicators of sustained revenue momentum. The improving financial profile may support a re-rating if Adjusted EBITDA continues to grow.
Price Chart
Executive Summary
Journey Medical Corporation reported FY2025 revenue of $61.9 million, a 10% increase from $56.1 million in FY2024, driven by the successful launch of Emrosi™, which generated $14.7 million in net revenue. Despite continued net loss narrowing to $11.4 million from $14.7 million, Adjusted EBITDA improved to $2.9 million, and gross margin expanded to 66.2%. The company also expanded payer access for Emrosi™ to over 100 million U.S. commercial lives.
Key Financial Metrics
Key Facts
- FY2025 revenue: $61.9 million (up 10% YoY from $56.1 million)
- Emrosi™ launched in April 2025, generated $14.7 million in net revenue in first year
- Gross margin improved to 66.2% from 62.8% in FY2024
- Net loss narrowed to $11.4 million from $14.7 million; EPS loss improved to $(0.47) from $(0.72)
- Adjusted EBITDA: $2.9 million in FY2025 vs. $0.8 million in FY2024
- Cash and cash equivalents increased to $24.1 million from $20.3 million
- Payer access for Emrosi™ expanded to over 100 million U.S. commercial lives by July 2025
Financial Impact
Revenue growth of $5.8 million YoY with expanding margins and improved cash flow; Adjusted EBITDA tripled to $2.9 million
Risk Factors
- Continued GAAP net losses despite improvements
- Reliance on Emrosi™ for growth amid competitive dermatology market
- Forward-looking statements with inherent uncertainty in commercial projections
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262557 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G/A | $6.31 | awaiting T+20 | — | $5.09 (−19.33%) |
Aug 15, 2026 10w ago | Institutional Cluster | $6.46 $7.36 | ▲ +13.93% | ▲ +15.91% | $5.09 (−21.21%) |
Aug 12, 2026 10w ago | 8-K | $6.65 $7.23 | ▲ +8.72% | ▲ +10.47% | $5.09 (−23.46%) |
Aug 12, 2026 10w ago | Press Release | $6.65 $7.23 | ▼ −8.72% | ▼ −10.47% | $5.09 (+23.46%) |
May 13, 2026 23w ago | 8-K | $6.35 $6.34 | ▼ −0.16% | ▲ +0.70% | $5.09 (−19.84%) |
May 6, 2026 24w ago | Press Release | $5.00 $6.06 | ▲ +21.20% | ▲ +18.06% | $5.09 (+1.80%) |
Apr 21, 2026 27w ago | Press Release | $4.92 $6.25 | ▲ +27.03% | ▲ +22.12% | $5.09 (+3.46%) |
Mar 25, 2026 30w ago | Press Release | $4.78 $5.15 | ▲ +7.74% | ▼ −2.92% | $5.09 (+6.49%) |
Mar 18, 2026 31w ago | Press Release | $7.12 $5.17 | ▼ −27.39% | ▼ −33.43% | $5.09 (−28.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers